Gene expression profiling of newly diagnosed plasma cell leukemia patients included in the HOVON129 clinical trial

This gene expression set contains data from patients included in the HOVON129 clinical trial. Using this data the relation between a signature identifying patients with aggressive biology and clinical parameters was studied in newly diagnosed plasma cell leukemia patients. This dataset was used to identify the relationship between a signature for aggressive disease and clinical parameters in plasma cell leukemia. 57 samples were analysed, which were taken from 29 individual patients. Samples were derived from bone marrow aspirates and peripheral blood samples, which were subjected to enrichment of PCL cells using CD138 specific beads. RNA sample workup was performed according to the instructions for use of the MMprofilers at the SkylineDx reference lab (SkylineDx, Rotterdam, The Netherlands). Samples were hybridized to Affymetrix HG-U133 plus2 chips, using Affymetrix Inc. (Santa Clara, CA) 3' IVT PLUS reagents. All samples passed wet lab and data QC acceptance criteria. Gene expressions were MAS5.0 normalized (values below 30 were truncated) with a target value of 1500.